Visualitzant per matèria "Trastuzumab"
Ara mostrant els elements 1-3 de 3
-
A Site-Specific MiniAp4–Trastuzumab Conjugate Prevents Brain Metastasis
(Molecular Pharmaceutics 2025, 22, 3, 1384–1395, 2025-03-03)Monoclonal antibodies (mAbs) are changing cancer treatments. However, the presence of the blood–brain barrier (BBB) and the blood–tumor barrier (BTB) limits the use of mAbs to treat brain cancer or brain ... -
An antibody-photosensitiser bioconjugate overcomes trastuzumab resistance in HER2-positive breast cancer
(European Journal of Medicinal Chemistry 2025, 290, 2025-06-05)HER2-positive breast cancer, characterized by the overexpression of HER2 receptors, often develops resistance to trastuzumab, limiting its therapeutic efficacy. In this study, we explore the use of ... -
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: preclinical and real-life clinical data
(The Breast, 2022, 62: 1-9, 2022-01)After the expiration of trastuzumab data exclusivity, biosimilar drugs were approved by regulatory agencies; among them, CT-P6 which was approved for the treatment of HER2-positive early- and advanced-breast ...